Humanigen (HGENQ) Azione Prezzo
Humanigen Prezzo
Il fatturato è cresciuto a un tasso composto del 11,8% annuo negli ultimi 13 anni, raggiungendo 2,51 Mio. USD. Il margine netto di Humanigen si attesta al -2817,9%, in calo rispetto al -385,4% di alcuni anni fa.
Humanigen Prezzo delle azioni
Humanigen Azione e analisi azionaria
Domande frequenti sull'azione Humanigen
The main competitors of Humanigen Inc in the market include pharmaceutical companies such as Eli Lilly and Company, Gilead Sciences Inc, and Regeneron Pharmaceuticals Inc.
Humanigen Inc is a biopharmaceutical company with a focus on advancing transformative monoclonal antibody therapeutics. Their business model revolves around developing and commercializing cutting-edge treatments to address unmet medical needs. Humanigen Inc utilizes its proprietary Humaneered® technology platform to create novel antibodies that target and neutralize disease-causing mechanisms in various diseases such as cancer and infectious diseases. Through strategic partnerships and collaborations, Humanigen Inc aims to bring innovative therapies to patients and improve their quality of life.
Humanigen Inc is primarily active in the biotechnology industry.
Humanigen Inc is a biopharmaceutical company specializing in developing and commercializing cutting-edge immunotherapies for various challenging diseases. Founded in 1997, Humanigen has a rich history in researching innovative treatments, including its proprietary Humaneered® antibody technology platform. With a focus on providing life-changing therapies, Humanigen strives to improve patient outcomes and enhance the quality of life for individuals worldwide. The company's dedication to advancing science and delivering effective solutions has positioned Humanigen as a leader in the biopharmaceutical industry.
Humanigen Inc has achieved several significant milestones. One notable accomplishment is the development of their lead product candidate, lenzilumab. This innovative monoclonal antibody has shown promise in treating various diseases, including COVID-19 and CAR-T therapy-related side effects. Humanigen Inc has also made progress in advancing clinical trials for lenzilumab, with positive results demonstrating its potential efficacy. Furthermore, the company has secured partnerships and collaborations to further enhance their research and development efforts. These milestones highlight Humanigen Inc's commitment to driving advancements in healthcare and their dedication to improving patient outcomes.
Humanigen Inc is primarily present in the United States.
Humanigen Inc represents values of innovation, dedication, and patient-centered care. As a biopharmaceutical company, Humanigen is committed to developing cutting-edge therapies to address unmet medical needs. With a focus on precision medicine and next-generation solutions, the company aims to improve the lives of patients worldwide. Humanigen Inc's corporate philosophy is centered around scientific excellence, ethical conduct, and a mission-driven approach to transform healthcare. By leveraging its expertise and collaborative partnerships, Humanigen strives to offer effective and accessible treatments to patients while ensuring the highest standards of quality and safety.
8 analisti valutano attualmente l’azione Humanigen: 0 raccomandano l’acquisto, 3 la tenuta e 5 la vendita.
L’azione Humanigen (HGENQ) è quotata su 4 borse, tra cui: NASDAQ (HGEN), Frankfurt (0KB2.F), München (0KB2.MU), Düsseldorf (0KB2.DU).
The company Humanigen Inc. is a biopharmaceutical company specializing in the development and marketing of treatments for rare and serious diseases. Its business model includes various sectors, including research and development, manufacturing and marketing of drugs, as well as research in collaboration with academic and nonprofit institutions.
Il fatturato non può essere attualmente calcolato per Humanigen.
Il profitto per Humanigen non può essere attualmente calcolato.
Il P/E per Humanigen non può essere attualmente calcolato.
L'indicatore Price-to-Sales (P/S) per Humanigen non può essere calcolato al momento.
Il Quality Score AlleAktien per Humanigen è 3/10.
L'ISIN di Humanigen è US4448632038. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Humanigen è A2QEQW. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Humanigen è HGENQ. Con questo simbolo di borsa vengono negoziate le azioni Humanigen in borsa.
Azione Humanigen
Gruppo di pari di Humanigen
Humanigen Ticker
Humanigen FIGI
Altre metriche e analisi di Humanigen in Deep Dive.
La nostra analisi azionaria dell'azione Humanigen include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Humanigen. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: